The Novartis in Society Integrated Report 2021 wins in the Reporting and Transparency category, with judges saying it ”demonstrates how businesses can go beyond the current paradigm, setting an encouraging standard for future reporting practices for all businesses”.

Learn more

Novartis was once again included in the Fortune World's Most Admired Companies list, gaining a score of 7.5 (2021: 7.4) in the survey. This year, over 3 700 executives, directors and analysts completed the survey, with a total of 640 companies across 28 countries participating. Novartis ranked #5 in the pharmaceuticals industry list.

Learn more

Paying tribute to those who stood up to the mark in a time of trouble and made a real impact within the community in terms of supporting them through the pandemic.

Learn more

Novartis rose to #3 in the Fortune World's Most Admired Companies Pharmaceuticals Industry list, from #4 in 2020 and 2019. Across the scored reputational dimensions, Novartis saw significant improvements in Social Responsibility (ranking as #4 most admired pharma company in this category in 2021 vs #8 in 2020) and Quality of Products (#4 in 2021 vs #7 in 2020). Novartis ranks #3 in Innovation and #2 In Global Competitiveness (the same as 2020).

Learn more

Novartis maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.

Learn more

Novartis is proud to be named one of the “Top 50 Most Innovative Companies in the World” by Boston Consulting Group. The list ranks companies based on a global survey of executives as well as the return they have produced for shareholders over the past three years.

Learn more

We are delighted to be recognized for our efforts as we continue to go big on learning.

Learn more

Novartis has again been ranked #4 by Fortune Magazine as one of the most admired pharmaceutical companies in the world.

Learn more

IdeaPharma’s PII ranks companies on their ability to bring products from early development to market and commercialize them successfully. Novartis moved up 9 spots, from #12 in 2017.

Learn more

Novartis has been named #1 most innovative biotech company and ranked #21 overall by Fast Company. The ranking identifies the most notable innovations of the year.

Learn more

Novartis is proud to once again rank #2 in the FORTUNE World's Most Admired Companies Pharmaceuticals Industry list. This is the third consecutive year that Novartis ranked as the second-most-admired company in our sector, and the 13th consecutive year that Novartis is in the top three.

Learn more

Novartis is again honored to be included in the 2017 “Top 10 Pipelines” list published by MedAdNews.

Learn more